1. Defender Capital opposes Alcon's acquisition of STAAR Surgical. 2. The proposed sale price of $28 significantly undervalues STAAR. 3. Defender urges STAAR to remain independent due to positive projections.
Opposition from major shareholders may destabilize investor confidence in ALC's acquisition target, STAAR, similar to past activist campaigns, which resulted in share price volatility.
The news of opposition to a planned acquisition can disrupt stock price trends, especially for ALC involved in the acquisition.
Short-term uncertainties due to investor sentiment regarding STAAR's sale could affect ALC's stock as the market reacts to developments.
CHARLOTTE, N.C., Oct. 7, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement outlining its opposition of the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE:ALC):
We have been significant STAAR shareholders for more than ten years and remain convicted in the significant value of the Company. The proposed sale of STAAR to Alcon for $28 per share significantly undervalues the Company, especially when considering the STAAR Board of Directors' rejection of Alcon's previous offer for $58 per share in cash only sixteen months ago.
With recent positive projections and outlook released by management, we see no compelling reason to sell STAAR at this time. We are disappointed that the Board has pursued this ill-advised transaction at a valuation that does not reflect the prospects of STAAR's business as a standalone company.
About
Defender Capital, an SEC-Registered Investment Advisor, manages investment accounts – retirement accounts, non-retirement accounts, trusts, corporate accounts, donor-advised funds, etc. – for individuals, families, and corporations. We take a research driven, long-term approach, investing in U.S. equities.
Contacts
ASC Advisors
Taylor Ingraham
tingraham@ascadvisors.com
203 992 1230
View original content:https://www.prnewswire.com/news-releases/defender-capital-opposes-staar-surgicals-proposed-sale-to-alcon-302577240.html
SOURCE Defender Capital